Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
881-900 of 998 trials

HER2-Positive Breast Cancer: New Treatment Without Chemotherapy

We are studying a combination of trastuzumab, pertuzumab, and tucatinib for patients with stage II-III HER2-positive breast cancer. The goal is to evaluate the safety and initial effectiveness of this chemotherapy-free approach.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Heart Attack Treatment: Evolocumab vs. Standard Care

We are studying whether the medication evolocumab can better prevent heart-related problems compared to standard treatments for patients who have recently had a heart attack. This trial focuses on improving cholesterol control and reducing hospitalizations.

Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Plozasiran for Severe Hypertriglyceridemia: SHASTA-5 Study

We are studying whether plozasiran can help adults with severe hypertriglyceridemia reduce their triglyceride levels and lower the risk of acute pancreatitis. The trial also looks at the treatment's safety and how it affects patients' overall health.

High Triglycerides>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

Ketamine Therapy for Obsessive-Compulsive Disorder

We are studying whether ketamine can effectively reduce symptoms of obsessive-compulsive disorder. This trial will help us understand its impact on mental function during stressful situations.

Obsessive Compulsive Disorder (OCD)≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

Prolonged Grief Disorder: PEX010 Treatment

We are testing a new treatment called PEX010 for people experiencing prolonged grief disorder. The study aims to see if it can significantly reduce grief symptoms and explore the effects of self-touch.

Prolonged Grief Disorder≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Fecal Incontinence: ICEF15 Therapy

We are testing a new treatment for fecal incontinence caused by anal sphincter weakness. The study aims to see if this therapy improves symptoms and enhances quality of life for patients.

Fecal Incontinence1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterology

Polymyalgia Rheumatica: Hydrocortisone Supplement Study

We are investigating whether supplemental hydrocortisone helps improve quality of life for patients with polymyalgia rheumatica or giant cell arteritis experiencing adrenal insufficiency. The focus is on how it affects fatigue during stress.

Glucocorticoid Induced Adrenal Insufficiency6-12 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Lung Cancer: JNJ-90301900 with Chemoradiation

We are studying a new drug combined with standard treatments for patients with advanced non-small cell lung cancer. The goal is to see if this combination improves treatment response.

Locally Advanced Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Multiple Sclerosis: CBD for Sleep Quality

We are investigating whether cannabidiol (CBD) can improve sleep quality in patients with multiple sclerosis. This study aims to help those struggling with sleep issues related to their condition.

Insomnia3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Lung Health: Avalyn Inhaled Antifibrotic Study

We are studying the long-term safety and effects of Avalyn's inhaled antifibrotic medications on lung function in patients who have previously participated in related trials.

Pulmonary FibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePulmonology

Crohn’s Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn’s disease. The goal is to see if it helps achieve remission and improve symptoms compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Idiopathic Pulmonary Fibrosis: CAL101 Treatment Study

We are studying whether CAL101 can improve lung function in patients with idiopathic pulmonary fibrosis compared to a placebo. The trial also looks at the safety of this new treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Acute Myeloid Leukemia: L-Annamycin with Cytarabine

We are studying a new treatment combining L-Annamycin with Cytarabine for adults with difficult-to-treat acute myeloid leukemia. The goal is to see if this combination can help achieve remission better than a placebo.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Chronic Inflammatory Demyelinating Polyneuropathy: Batoclimab Study

We are studying the long-term safety and tolerability of batoclimab in adults with CIDP. This trial aims to see how well the medication works for managing symptoms over time.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Wiskott-Aldrich Syndrome: Long-term Study of Gene Therapy

We are examining the long-term safety and effectiveness of a gene therapy treatment for individuals with Wiskott-Aldrich Syndrome. This study aims to provide insights into how well the treatment works over time.

Wiskott-Aldrich Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

Ketamine for Treating Disorders of Consciousness After Coma

We are studying whether intravenous ketamine can help patients regain consciousness after a coma. The trial also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyPsychiatry

Heart Failure: PF-07328948 Study

We are testing a new oral medication for adults with heart failure to see if it improves heart function and symptoms compared to a placebo. The study also examines the safety of this treatment.

Heart Failure6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Kidney Disease: Vicadrostat and Empagliflozin Study

We are investigating whether starting vicadrostat with empagliflozin helps people with chronic kidney disease. The study compares two different ways of starting the medications to see which is more effective.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteDiabetologyNephrology

Immune Thrombocytopenia: Pirtobrutinib Study

We are investigating a new medication, pirtobrutinib, for adults with immune thrombocytopenia. The study aims to assess its safety and effectiveness compared to a placebo.

Immune Thrombocytopenia≤3 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteHematology

Ischemic Stroke: Thrombolytic Therapy with rtPA

We are studying a new treatment for patients with acute ischemic stroke who are on blood thinners. The goal is to see if this therapy improves recovery compared to a placebo after reversing the blood thinner's effects.

Ischaemic Stroke3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology